GoldenGolden
Advanced Search

Menlo Therapeutics

A clinical late-stage biopharmaceutical company in California that focuses on treatments of dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis.

Menlo Therapeutics is a clinical late-stage biopharmaceutical company in California that focuses on treatments of dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. Founded 2011 in Menlo Park, California, United States, Menlo Therapeutics is focused on large and growing markets in dermatology. It has two commercial products: AMZEEQ® and ZILXI™, which employ proprietary differentiated Molecule Stabilizing Technology (MST). This proprietary technology stabilizes hydrophobic molecules and leads to a surfactant and irritant-free formulation designed to maintain barrier function, improve tolerability and compliance. It leads to a low mechanical shear designed to enhance spreadability and has the capability to deliver unstable drugs that have been difficult to formulate topically. This technology enabled the development of the first topical minocycline.

The pipeline products of the company deal with prurigo nodularis, prurigo dermatitis, psoriasis and refractory chronic cough. Menlo Therapeutics has combined with Foamix Pharmaceuticals creating a leading biopharma company focused on the commercialization and development of therapeutics to serve patients in the dermatology space.

Timeline

July 2017
Menlo Therapeutics raises a $50,000,000 series C round from Aisling Capital, Bay City Capital, F-Prime Capital Partners, Novo Holdings A/S, Presidio Partners, Remeditex Ventures, Rock Springs Capital, Vivo Capital and venBio.
2011
Founded

Funding rounds

People

Name
Role
LinkedIn

Emmanuelle Bellemin

Vice President of Regulatory Affairs and Quality Assurance

Mark P. Joing

Vice President of Clinical Operations

Steve Basta

Chief Executive Officer

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Mark Terry
June 1, 2020
BioSpace
Although the U.S. FDA is very busy dealing with emergency use approvals for diagnostics and possible treatments for COVID-19, it is still evaluating and approving therapies for non-COVID-19 indications. Here's a look at this week's calendar.
Alex Keown
May 22, 2020
BioSpace
Pharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.